Carcinoma, Hepatocellular
Showing NaN - NaN of 45
Carcinoma, Hepatocellular Trial in Worldwide (drug, biological, procedure)
Active, not recruiting
- Carcinoma, Hepatocellular
- Lenvatinib
- +4 more
-
Tucson, Arizona
- +206 more
Jan 31, 2023
Carcinoma, Hepatocellular, Biliary Tract Cancer, Secondary Liver Cancer Trial in Worldwide (RO7119929, Tocilizumab)
Completed
- Carcinoma, Hepatocellular
- +3 more
-
Duarte, California
- +9 more
Jan 27, 2023
Carcinoma, Hepatocellular, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Seoul (Microwave ablation)
Active, not recruiting
- Carcinoma, Hepatocellular
- +3 more
- Microwave ablation
-
Seoul, Korea, Republic ofSamsung Medical Center
Jan 23, 2023
Lenvima in Korean Unresectable Hepatocellular Carcinoma
Completed
- Liver Neoplasms
- Carcinoma, Hepatocellular
- Non-interventional
-
Cheonan, Chungcheongnam-do, Korea, Republic of
- +41 more
Jan 6, 2023
Carcinoma, Hepatocellular, Hepatoma Trial in Seongnam, Seoul (Regorafenib/Nivolumab)
Completed
- Carcinoma, Hepatocellular
- Hepatoma
-
Seongnam, Korea, Republic of
- +2 more
Dec 4, 2022
Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg)
Completed
- Carcinoma, Hepatocellular
- Tepotinib 300 mg
- +4 more
-
Beijing, Beijing, China
- +42 more
Aug 22, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab)
Active, not recruiting
- Carcinoma, Hepatocellular
-
Los Angeles, California
- +138 more
Aug 22, 2022
Carcinoma, Hepatocellular, Colorectal Tumors, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Pembrolizumab, Belzutifan,
Recruiting
- Carcinoma, Hepatocellular
- +5 more
- Pembrolizumab
- +2 more
-
Duarte, California
- +39 more
Jul 29, 2022
Carcinoma, Hepatocellular Trial in Worldwide (Atezolizumab, Bevacizumab, Sorafenib)
Active, not recruiting
- Carcinoma, Hepatocellular
- Atezolizumab
- +2 more
-
Phoenix, Arizona
- +118 more
Jun 14, 2022
Carcinoma, Hepatocellular, Body Weight Trial in Seoul (low dose CT contrast media - lean body weight, Standard dose CT contrast
Completed
- Carcinoma, Hepatocellular
- Body Weight
- low dose CT contrast media - lean body weight
- Standard dose CT contrast media
-
Seoul, Korea, Republic ofSeoul National University Hospital
Apr 27, 2022
Carcinoma, Hepatocellular Trial in Worldwide (biological, drug, other)
Active, not recruiting
- Carcinoma, Hepatocellular
- pembrolizumab
- +2 more
-
Hefei, Anhui, China
- +40 more
Mar 3, 2022
Carcinoma, Hepatocellular Trial in Seoul (Theraspere)
Completed
- Carcinoma, Hepatocellular
- Theraspere
-
Seoul, Korea, Republic ofSeoul National University Hospital
Aug 31, 2021
Carcinoma, Hepatocellular Trial in Seoul (Immuncell-LC)
Active, not recruiting
- Carcinoma, Hepatocellular
- Immuncell-LC
-
Seoul, Banpo-daero 222 / Seocho-go, Korea, Republic of
- +2 more
Apr 14, 2021
Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766), Sorafenib (BAY43-9006))
Completed
- Carcinoma, Hepatocellular
- Refametinib (BAY86-9766)
- Sorafenib (BAY43-9006)
-
Louisville, Kentucky
- +78 more
Apr 6, 2021
Carcinoma, Hepatocellular Trial in Worldwide (Refametinib (BAY86-9766))
Completed
- Carcinoma, Hepatocellular
- Refametinib (BAY86-9766)
-
Washington, District of Columbia
- +57 more
Apr 6, 2021
Carcinoma, Hepatocellular Trial in Seoul (No-touch RFA arm, Conventional tumor puncture RFA arm)
Recruiting
- Carcinoma, Hepatocellular
- No-touch RFA arm
- Conventional tumor puncture RFA arm
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 17, 2021
Radiofrequency Ablation, Carcinoma, Hepatocellular Trial in Seoul (RFA using combined bipolar and monopolar energy deliver)
Recruiting
- Radiofrequency Ablation
- Carcinoma, Hepatocellular
- RFA using combined bipolar and monopolar energy deliver
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 16, 2021
Carcinoma, Hepatocellular Trial in Seoul (Avelumab)
Completed
- Carcinoma, Hepatocellular
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 15, 2021
Radiofrequency Ablation, Carcinoma, Hepatocellular Trial in Seoul (RFA using gradual RF energy delivery mode with Octopus
Recruiting
- Radiofrequency Ablation
- Carcinoma, Hepatocellular
- RFA using gradual RF energy delivery mode with Octopus electrodes
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 16, 2021
Carcinoma, Hepatocellular Trial in Worldwide (Regorafenib (Stivarga, BAY73-4506), Placebo)
Completed
- Carcinoma, Hepatocellular
- Regorafenib (Stivarga, BAY73-4506)
- Placebo
-
Los Angeles, California
- +146 more
Aug 11, 2020
Carcinoma, Hepatocellular Trial in China, Korea, Republic of, Taiwan (JNJ-42756493 (erdafitinib))
Completed
- Carcinoma, Hepatocellular
- JNJ-42756493 (erdafitinib)
-
Changchun, China
- +9 more
Feb 17, 2020
Carcinoma, Hepatocellular Trial in Worldwide (Sorafenib (Nexavar, BAY43-9006), Erlotinib (Tarceva), Placebo)
Completed
- Carcinoma, Hepatocellular
- Sorafenib (Nexavar, BAY43-9006)
- +2 more
-
San Francisco, California
- +126 more
May 16, 2019
Carcinoma, Hepatocellular, Chronic Hepatitis B Trial in Seoul (PEIT, RFTA)
Completed
- Carcinoma, Hepatocellular
- Chronic Hepatitis B
- PEIT
- RFTA
-
Seoul, Korea, Republic ofSeoul National University Hospital
Mar 14, 2019